Valuation: Evelo Biosciences, Inc.

Market Cap 1.17M 1.04M 961K 874K 1.65M 111M 1.68M 11.55M 4.53M 57.77M 4.38M 4.28M 184M P/E 2021
-2.63x
P/E 2022 -1.23x
Enterprise Value 4.36M 3.88M 3.6M 3.27M 6.17M 414M 6.27M 43.22M 16.95M 216M 16.38M 16.03M 689M EV / Sales 2021
-
EV / Sales 2022 -
Free-Float
100%
Yield 2021 *
-
Yield 2022 -
1 day-80.00%
1 week-50.00%
1 month+9,900.00%
3 months+9,900.00%
Current year-80.00%
1 month 0
Extreme 0.0001
0
Current year 0
Extreme 1.0E-6
0
1 year 0
Extreme 1.0E-6
0
3 years 0
Extreme 1.0E-6
1.05
5 years 0
Extreme 1.0E-6
254.8
10 years 0
Extreme 1.0E-6
398.57
Manager TitleAgeSince
Chief Executive Officer 65 2023-11-20
Director TitleAgeSince
Director/Board Member 65 2023-11-20
Date Insider Type Main position Quantity % Market Cap. Importance
11/7/23 Exercice

Chief Financial Officer

14,811 0.0786%
11/7/23 Exercice

Chief Executive Officer

2,516 0.0134%
11/7/23 Exercice

Chief Technology Officer

16,413 0.0871%
Change 5-day change 1-year change 3-year change Capi.($)
-80.00%-50.00%-50.00%-99.99% 3.8K
-6.60%-8.56%+49.38%+63.51% 65B
-4.09%-0.11%+2.22%+53.15% 51.19B
+0.03%+5.56%+9.10%+69.05% 51.2B
-1.53%+2.70%+30.48%+34.12% 43.93B
-1.34%+4.12%+16.64%+115.13% 41.96B
-5.97%-6.22%+228.95%+454.22% 38.14B
+6.53%+8.02%+16.40%+53.41% 33.24B
-0.90%-10.49%+37.09%-3.70% 25.2B
-2.76%-9.54%-16.58%-9.19% 22.03B
Average -9.66%-1.50%+32.37%+72.97% 37.19B
Weighted average by Cap. -2.30%-1.21%+42.14%+95.51%

Financials

2021 2022
Net sales - -
Net income -122M -109M -101M -91.58M -173M -11.6B -176M -1.21B -474M -6.05B -459M -449M -19.29B -115M -102M -94.36M -85.85M -162M -10.87B -165M -1.13B -445M -5.67B -430M -421M -18.08B
Net Debt -12.15M -10.8M -10.01M -9.11M -17.18M -1.15B -17.46M -120M -47.17M -602M -45.59M -44.62M -1.92B 3.2M 2.84M 2.63M 2.4M 4.52M 304M 4.6M 31.67M 12.42M 158M 12M 11.75M 505M
Logo Evelo Biosciences, Inc.
Evelo Biosciences, Inc. is a clinical-stage biotechnology company. The Company is focused on discovering and developing a class of oral medicines that act on immune cells in the small intestine with systemic effects. Its small intestinal axis (SINTAX) is the network of connections that links the small intestine and the rest of the body. Immune cells and other cells in the small intestine act as sentinels and are constantly sensing the contents of the gut. Depending on what is sensed, these cells relay messages from the gut to the rest of the body that modulate systemic immunity. Its orally delivered product candidates are pharmaceutical compositions of specific single strains of commensal microbes or the extracellular vesicles (EVs) they shed.
Employees
66
  1. Stock Market
  2. Stocks
  3. EVLO Stock